Loss of ACAT1 Attenuates Atherosclerosis Aggravated by Loss of NCEH1 in Bone Marrow-Derived Cells

Overview

Journal J Atheroscler Thromb

Date 2018 Oct 5

PMID 30282838

Citations 2

Authors

Hisataka Yamazaki

Manabu Takahashi

Tetsuji Wakabayashi

Kent Sakai

Daisuke Yamamuro

Akihito Takei

Shoko Takei

Shuichi Nagashima

Hiroaki Yagyu

Motohiro Sekiya

Ken Ebihara

Shun Ishibashi

Affiliations

Soon will be listed here.

Abstract

Aim: Acyl-CoA cholesterol acyltransferase 1 (ACAT1) esterifies free cholesterol to cholesteryl esters (CE), which are subsequently hydrolyzed by neutral cholesterol ester hydrolase 1 (NCEH1). The elimination of ACAT1 in vitro reduces the amounts of CE accumulated in Nceh1-deficient macrophages. The present study aimed at examining whether the loss of ACAT1 attenuates atherosclerosis which is aggravated by the loss of NCEH1 in vivo.

Methods: Low density lipoprotein receptor (Ldlr)-deficient mice were transplanted with bone marrow from wild-type mice and mice lacking ACAT1, NCEH1, or both. The four types of mice were fed a high-cholesterol diet and, then, were examined for atherosclerosis.

Results: The cross-sectional lesion size of the recipients of Nceh1-deficient bone marrow was 1.6-fold larger than that of the wild-type bone marrow. The lesions of the recipients of Nceh1-deficient bone marrow were enriched with MOMA2-positive macrophages compared with the lesions of the recipients of the wild-type bone marrow. The size and the macrophage content of the lesions of the recipients of bone marrow lacking both ACAT1 and NCEH1 were significantly smaller than the recipients of the Nceh1-deficient bone marrow, indicating that the loss of ACAT1 decreases the excess CE in the Nceh1-deficient lesions. The collagen-rich and/or mucin-rich areas and en face lesion size were enlarged in the recipients of the Acat1 bone marrow compared with those of the recipients of the WT bone marrow.

Conclusion: The loss of ACAT1 in bone marrow-derived cells attenuates atherosclerosis, which is aggravated by the loss of NCEH1, corroborating the in vitro functions of ACAT1 (formation of CE) and NCEH1 (hydrolysis of CE).

Citing Articles

ISG15 Is a Novel Regulator of Lipid Metabolism during Infection.

Albert M, Vazquez J, Falcon-Perez J, Balboa M, Liesa M, Balsinde J Microbiol Spectr. 2022; 10(6):e0389322.

PMID: 36453897 PMC: 9769738. DOI: 10.1128/spectrum.03893-22.

Myeloid / KO attenuates pro-inflammatory responses in macrophages and protects against atherosclerosis in a model of advanced lesions.

Melton E, Li H, Benson J, Sohn P, Huang L, Song B J Biol Chem. 2019; 294(43):15836-15849.

PMID: 31495784 PMC: 6816086. DOI: 10.1074/jbc.RA119.010564.

References

Bocan T, Krause B, Rosebury W, Mueller S, Lu X, Dagle C . The ACAT inhibitor avasimibe reduces macrophages and matrix metalloproteinase expression in atherosclerotic lesions of hypercholesterolemic rabbits. Arterioscler Thromb Vasc Biol. 2000; 20(1):70-9. DOI: 10.1161/01.atv.20.1.70. View

Osuga J, Ishibashi S, Oka T, Yagyu H, Tozawa R, Fujimoto A . Targeted disruption of hormone-sensitive lipase results in male sterility and adipocyte hypertrophy, but not in obesity. Proc Natl Acad Sci U S A. 2000; 97(2):787-92. PMC: 15409. DOI: 10.1073/pnas.97.2.787. View

Yagyu H, Kitamine T, Osuga J, Tozawa R, Chen Z, Kaji Y . Absence of ACAT-1 attenuates atherosclerosis but causes dry eye and cutaneous xanthomatosis in mice with congenital hyperlipidemia. J Biol Chem. 2000; 275(28):21324-30. DOI: 10.1074/jbc.M002541200. View

Fazio S, Major A, Swift L, Gleaves L, Accad M, Linton M . Increased atherosclerosis in LDL receptor-null mice lacking ACAT1 in macrophages. J Clin Invest. 2001; 107(2):163-71. PMC: 198874. DOI: 10.1172/JCI10310. View

Delsing D, Offerman E, van Duyvenvoorde W, van der Boom H, de Wit E, Gijbels M . Acyl-CoA:cholesterol acyltransferase inhibitor avasimibe reduces atherosclerosis in addition to its cholesterol-lowering effect in ApoE*3-Leiden mice. Circulation. 2001; 103(13):1778-86. DOI: 10.1161/01.cir.103.13.1778. View

Kusunoki J, Hansoty D, Aragane K, Fallon J, Badimon J, Fisher E . Acyl-CoA:cholesterol acyltransferase inhibition reduces atherosclerosis in apolipoprotein E-deficient mice. Circulation. 2001; 103(21):2604-9. DOI: 10.1161/01.cir.103.21.2604. View

Usui S, Hara Y, Hosaki S, Okazaki M . A new on-line dual enzymatic method for simultaneous quantification of cholesterol and triglycerides in lipoproteins by HPLC. J Lipid Res. 2002; 43(5):805-14. View

Movat H . Demonstration of all connective tissue elements in a single section; pentachrome stains. AMA Arch Pathol. 1955; 60(3):289-95. View

HAVEL R, EDER H, Bragdon J . The distribution and chemical composition of ultracentrifugally separated lipoproteins in human serum. J Clin Invest. 1955; 34(9):1345-53. PMC: 438705. DOI: 10.1172/JCI103182. View

10.

Namatame I, Tomoda H, Ishibashi S, Omura S . Antiatherogenic activity of fungal beauveriolides, inhibitors of lipid droplet accumulation in macrophages. Proc Natl Acad Sci U S A. 2004; 101(3):737-42. PMC: 321750. DOI: 10.1073/pnas.0307757100. View

11.

Rong J, Kusunoki J, Oelkers P, Sturley S, Fisher E . Acyl-coenzymeA (CoA):cholesterol acyltransferase inhibition in rat and human aortic smooth muscle cells is nontoxic and retards foam cell formation. Arterioscler Thromb Vasc Biol. 2004; 25(1):122-7. DOI: 10.1161/01.ATV.0000148202.49842.3b. View

12.

Tardif J, Gregoire J, LAllier P, Anderson T, Bertrand O, Reeves F . Effects of the acyl coenzyme A:cholesterol acyltransferase inhibitor avasimibe on human atherosclerotic lesions. Circulation. 2004; 110(21):3372-7. DOI: 10.1161/01.CIR.0000147777.12010.EF. View

13.

Ru Su Y, Dove D, Major A, Hasty A, Boone B, Linton M . Reduced ABCA1-mediated cholesterol efflux and accelerated atherosclerosis in apolipoprotein E-deficient mice lacking macrophage-derived ACAT1. Circulation. 2005; 111(18):2373-81. DOI: 10.1161/01.CIR.0000164236.19860.13. View

14.

Nissen S, Tuzcu E, Brewer H, Sipahi I, Nicholls S, Ganz P . Effect of ACAT inhibition on the progression of coronary atherosclerosis. N Engl J Med. 2006; 354(12):1253-63. DOI: 10.1056/NEJMoa054699. View

15.

Terasaka N, Miyazaki A, Kasanuki N, Ito K, Ubukata N, Koieyama T . ACAT inhibitor pactimibe sulfate (CS-505) reduces and stabilizes atherosclerotic lesions by cholesterol-lowering and direct effects in apolipoprotein E-deficient mice. Atherosclerosis. 2006; 190(2):239-47. DOI: 10.1016/j.atherosclerosis.2006.03.007. View

16.

Ikenoya M, Yoshinaka Y, Kobayashi H, Kawamine K, Shibuya K, Sato F . A selective ACAT-1 inhibitor, K-604, suppresses fatty streak lesions in fat-fed hamsters without affecting plasma cholesterol levels. Atherosclerosis. 2006; 191(2):290-7. DOI: 10.1016/j.atherosclerosis.2006.05.048. View

17.

Okazaki H, Igarashi M, Nishi M, Sekiya M, Tajima M, Takase S . Identification of neutral cholesterol ester hydrolase, a key enzyme removing cholesterol from macrophages. J Biol Chem. 2008; 283(48):33357-64. PMC: 2662263. DOI: 10.1074/jbc.M802686200. View

18.

Chang T, Li B, Chang C, Urano Y . Acyl-coenzyme A:cholesterol acyltransferases. Am J Physiol Endocrinol Metab. 2009; 297(1):E1-9. PMC: 2711667. DOI: 10.1152/ajpendo.90926.2008. View

19.

Meuwese M, de Groot E, Duivenvoorden R, Trip M, Ose L, Maritz F . ACAT inhibition and progression of carotid atherosclerosis in patients with familial hypercholesterolemia: the CAPTIVATE randomized trial. JAMA. 2009; 301(11):1131-9. DOI: 10.1001/jama.301.11.1131. View

20.

Igarashi M, Osuga J, Isshiki M, Sekiya M, Okazaki H, Takase S . Targeting of neutral cholesterol ester hydrolase to the endoplasmic reticulum via its N-terminal sequence. J Lipid Res. 2009; 51(2):274-85. PMC: 2803229. DOI: 10.1194/jlr.M900201-JLR200. View